Rhythm Pharmaceuticals, INC.
Forward trial catalysts linked to RYTM
CSA tracks 1 forward catalyst for Rhythm Pharmaceuticals, INC. across 1 asset, spanning Phase 3. The nearest is a readout expected Mar 13, 2027 (day precision). Confidence across its tracked catalysts breaks down as 1 medium. Tracked indications include Hypothalamic Obesity.
RYTM in the full snapshot
The free sample on this page is a slice. In the current full CSA snapshot, Rhythm Pharmaceuticals, INC. has:
Forward catalysts by year
Every catalyst in the snapshot comes with its date, date confidence and source link.
2 trials behind these assets
| Asset | Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|---|
| setmelanotide | NCT05774756 | Phase 3 | Active, not recruiting | 2025-03-18 | Experimental | Rhythm Pharmaceuticals, Inc. | Hypothalamic Obesity |
| setmelanotide | NCT06760546 catalyst | Phase 3 | Recruiting | 2027-03-13 | Experimental | Rhythm Pharmaceuticals, Inc. | Hypothalamic Obesity; Multiple Pituitary Hormone Deficiency Genetic Form; Septo-Optic Dysp… |
Every trial the CSA sample links to RYTM's tracked assets.
Conditions studied
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This sponsor's catalysts are a slice of the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 →